G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Estrogen Signaling Research

Executive Summary: G-1 (CAS 881639-98-1) is a potent, selective agonist for the G protein-coupled estrogen receptor GPR30 (GPER1), exhibiting a Ki of ~11 nM and negligible affinity for classical nuclear estrogen receptors ERα and ERβ at micromolar concentrations [APExBIO]. Upon GPR30 activation, G-1 triggers rapid intracellular signaling, notably calcium mobilization (EC50 = 2 nM) and PI3K pathway activation [Wang et al., 2021]. In vitro, G-1 inhibits breast cancer cell migration (IC50: SKBr3 0.7 nM, MCF7 1.6 nM) and, in vivo, attenuates cardiac fibrosis and improves contractility in heart failure models. G-1 is a crystalline solid (MW 412.28, C21H18BrNO3), DMSO-soluble (≥41.2 mg/mL), and must be stored at -20°C for short-term use. APExBIO supplies G-1 (B5455), the gold-standard for studying rapid, non-genomic estrogen signaling.

Biological Rationale

The G protein-coupled estrogen receptor (GPR30/GPER1) mediates rapid, non-genomic estrogen signaling. Unlike classical nuclear estrogen receptors ERα and ERβ, GPR30 is an integral membrane protein localized primarily to the endoplasmic reticulum [Wang et al., 2021]. GPR30 activation by selective agonists like G-1 modulates intracellular calcium and PI3K signaling, leading to distinct physiological outcomes. In immune cells, GPR30 signaling normalizes CD4+ T lymphocyte function following hemorrhagic shock, highlighting its importance in immune homeostasis [Wang et al., 2021]. GPR30 is also implicated in cardioprotection and inhibition of cancer cell migration, making it a critical target in translational research.

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds to GPR30 with high affinity (Ki ~11 nM), displaying negligible activity at ERα and ERβ even at 1 μM, ensuring exceptional receptor selectivity [APExBIO]. Upon binding, G-1 induces conformational changes in GPR30, triggering downstream signaling cascades:

• Intracellular Calcium Mobilization: G-1 increases cytosolic Ca²⁺ levels (EC50 = 2 nM), a hallmark of rapid GPCR-mediated estrogen signaling [Wang et al., 2021].
• PI3K/Akt Pathway: G-1 promotes PI3K-dependent nuclear accumulation of PIP3, facilitating cell survival and metabolic responses.
• Cardiac Pathways: In heart failure models, G-1 normalizes β1-adrenergic receptor expression and upregulates β2-adrenergic receptor, contributing to improved contractility and reduced fibrosis [Related].

This mechanism contrasts with nuclear ER signaling, which primarily regulates gene expression over longer timescales.

Evidence & Benchmarks

• G-1 binds GPR30 with a Ki of ~11 nM, demonstrating >100-fold selectivity over ERα and ERβ (APExBIO, product page).
• G-1 rapidly increases cytosolic Ca²⁺ (EC50 = 2 nM) in GPR30-expressing cells (Wang et al., 2021, DOI).
• Suppresses breast cancer cell migration (IC50: 0.7 nM in SKBr3; 1.6 nM in MCF7) (APExBIO, product page).
• Chronic G-1 administration reduces brain natriuretic peptide (BNP) levels and cardiac fibrosis in ovariectomized female rat heart failure models (Wang et al., 2021, DOI).
• G-1, but not ERβ agonists, restores CD4+ T lymphocyte proliferation post-hemorrhagic shock, confirming GPR30 specificity (Wang et al., 2021, DOI).
• G-1 effects are blocked by GPR30 antagonists (e.g., G15), further verifying on-target mechanism (Wang et al., 2021, DOI).

For an in-depth strategic perspective, see "Harnessing GPR30 Activation: Strategic Insights for Translational Research" (external link), which discusses how this article updates clinical translation and workflow integration not covered elsewhere.

Applications, Limits & Misconceptions

G-1 is used to dissect rapid estrogen signaling in cardiovascular, cancer, and immunological models. It is particularly valuable for:

• Characterizing non-genomic estrogen effects in vitro and in vivo.
• Evaluating GPR30’s role in cardiac remodeling, contractility, and fibrosis.
• Studying inhibition of breast cancer cell migration and invasion.
• Elucidating rapid estrogen-mediated immune modulation.

For a detailed comparison of G-1’s translational applications, see "G-1: Selective GPR30 Agonist for Cardiovascular and Cancer Research" (external link), which this article extends by incorporating new in vivo cardiac and immune data.

Common Pitfalls or Misconceptions

• Not a pan-estrogen receptor agonist: G-1 has negligible activity at ERα and ERβ at experimental concentrations; it does not recapitulate classical nuclear estrogen effects [Wang et al., 2021].
• Water and ethanol insolubility: G-1 is insoluble in water and ethanol; DMSO is required for stock preparation [APExBIO].
• Not suitable for chronic long-term storage in solution: Degradation occurs; stocks should be freshly prepared and stored at -20°C for short durations.
• GPR30 antagonist or ER antagonists can block effects: Use of G15 or ICI 182,780 can abrogate G-1 responses, confirming on-target effects [Wang et al., 2021].
• Not a suitable substitute for ERα/ERβ studies: Use G-1 specifically when GPR30-selective activation is required.

This article builds on "G-1: Selective GPR30 Agonist Empowering Cardiovascular and Cancer Research" (external link), clarifying experimental boundaries and latest cardiac data.

Workflow Integration & Parameters

• Formulation: G-1 is supplied as a crystalline solid (MW 412.28, C21H18BrNO3).
• Solubility: Soluble in DMSO at ≥41.2 mg/mL; insoluble in water and ethanol.
• Stock Preparation: Prepare >10 mM stocks in DMSO; use warming and ultrasonic bath to enhance solubility.
• Storage: Store solutions at -20°C; avoid long-term storage to prevent degradation.
• Recommended Use: For in vitro and in vivo studies of GPR30-mediated signaling.

For validated experimental protocols and further best practices, reference the APExBIO G-1 product page and the B5455 kit documentation.

Conclusion & Outlook

G-1 (CAS 881639-98-1) is the gold-standard selective GPR30 agonist for dissecting rapid, non-genomic estrogen signaling. Its unique selectivity, potency, and validated performance in cardiovascular, immune, and cancer models have enabled key mechanistic and translational discoveries. APExBIO’s G-1 (B5455) is recommended for researchers requiring reproducible, on-target GPR30 activation. Ongoing research is expanding GPR30’s therapeutic potential in heart failure, immunity, and oncology. For related mechanistic depth and future directions, see "G-1 (CAS 881639-98-1): Redefining Rapid Estrogen Signaling" (external link), which this article extends with updated immune and cardiac evidence.